Literature DB >> 26292082

Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.

Bogdan J Wlodarczyk1, Krystal Ogle1, Linda Ying Lin1, Meir Bialer2, Richard H Finnell1,3.   

Abstract

OBJECTIVES: Based on the recent findings from animal studies, it has been proposed that the therapeutic use of valnoctamide, an anxiolytic drug developed in the early 1960s, be extended to treat other neurological disorders such as epilepsy and bipolar disease. Given the scarcity of adequate data on its prenatal toxicity, a comparative teratogenicity study of valnoctamide and two of the most commonly used drugs to treat bipolar disorder, risperidone and olanzapine, was carried out in a mouse model system.
METHODS: Pregnant dams were treated with the aforementioned three drugs at the dose levels calculated as an equal proportion of the respective LD50 values of these drugs. The main reproductive indices examined included the numbers of implantations and resorptions, viable and dead fetuses, and fetal gross, visceral and skeletal abnormalities.
RESULTS: The outcomes of the present study indicated that olanzapine was the most teratogenic of the three drugs, inducing maternal-, embryo-, and fetotoxicity. Risperidone also exerted a significant prenatal toxicity, but its adverse effect was less pronounced than that induced by olanzapine. Valnoctamide did not show any teratogenic effect, even when used in relatively higher dosages than olanzapine and risperidone. The observed increased skeletal abnormalities in one of the valnoctamide treatment groups were nonspecific and, as such, signaled a modest developmental delay rather than an indication that the compound could induce structural malformations.
CONCLUSIONS: Under our experimental conditions, valnoctamide demonstrated the lowest prenatal toxicity of the three tested drugs.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  comparative teratogenicity; mice; olanzapine; risperidone; valnoctamide

Mesh:

Substances:

Year:  2015        PMID: 26292082      PMCID: PMC4631615          DOI: 10.1111/bdi.12325

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  36 in total

1.  Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.

Authors:  J Morrow; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; R C McGivern; P J Morrison; J Craig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-12       Impact factor: 10.154

Review 2.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 3.  Valproic Acid: second generation.

Authors:  Meir Bialer; Boris Yagen
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

Review 4.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

5.  Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity.

Authors:  Elena Menegola; Francesca Di Renzo; Maria L Broccia; Michela Prudenziati; Saverio Minucci; Valentina Massa; Erminio Giavini
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2005-10

6.  Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid.

Authors:  Jakob Avi Shimshoni; Meir Bialer; Bogdan Wlodarczyk; Richard H Finnell; Boris Yagen
Journal:  J Med Chem       Date:  2007-11-10       Impact factor: 7.446

Review 7.  Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  Cynthia L Harden; Kimford J Meador; Page B Pennell; W Allen Hauser; Gary S Gronseth; Jacqueline A French; Samuel Wiebe; David Thurman; Barbara S Koppel; Peter W Kaplan; Julian N Robinson; Jennifer Hopp; Tricia Y Ting; Barry Gidal; Collin A Hovinga; Andrew N Wilner; Blanca Vazquez; Lewis Holmes; Allan Krumholz; Richard Finnell; Deborah Hirtz; Claire Le Guen
Journal:  Epilepsia       Date:  2009-05       Impact factor: 5.864

8.  Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing.

Authors:  Galit Shaltiel; Shaltiel Galit; Shirley Mark; Mark Shirley; Ora Kofman; Kofman Ora; Robert H Belmaker; Galila Agam; Agam Galila
Journal:  Pharmacol Rep       Date:  2007 Jul-Aug       Impact factor: 3.024

9.  Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.

Authors:  Kimford J Meador; Gus A Baker; Nancy Browning; Jill Clayton-Smith; Deborah T Combs-Cantrell; Morris Cohen; Laura A Kalayjian; Andres Kanner; Joyce D Liporace; Page B Pennell; Michael Privitera; David W Loring
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

Review 10.  Teratogenesis associated with antibipolar agents.

Authors:  Ha T T Nguyen; Verinder Sharma; Roger S McIntyre
Journal:  Adv Ther       Date:  2009-03-28       Impact factor: 3.845

View more
  7 in total

1.  Valnoctamide Inhibits Cytomegalovirus Infection in Developing Brain and Attenuates Neurobehavioral Dysfunctions and Brain Abnormalities.

Authors:  Sara Ornaghi; Lawrence S Hsieh; Angélique Bordey; Patrizia Vergani; Michael J Paidas; Anthony N van den Pol
Journal:  J Neurosci       Date:  2017-06-19       Impact factor: 6.167

2.  Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder.

Authors:  Hiren R Modi; Kaizong Ma; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Psychiatry Res       Date:  2017-04-26       Impact factor: 3.222

3.  Novel report on congenital talipes equinovarus (CTEV) following olanzapine exposure during pregnancy: case report and short review.

Authors:  Rajan Gyawali; Ashok Baral; Dikshya Upreti; Chandra Bhushan Yadav; Anoop Krishna Gupta; Miyuru Chandradasa; Sheikh Shoib
Journal:  Arch Womens Ment Health       Date:  2022-03-14       Impact factor: 3.633

4.  Mood stabilizers inhibit cytomegalovirus infection.

Authors:  Sara Ornaghi; John N Davis; Kelly L Gorres; George Miller; Michael J Paidas; Anthony N van den Pol
Journal:  Virology       Date:  2016-09-19       Impact factor: 3.616

5.  Mitochondrial Liver Toxicity of Valproic Acid and Its Acid Derivatives Is Related to Inhibition of α-Lipoamide Dehydrogenase.

Authors:  Alexei P Kudin; Hafiz Mawasi; Arik Eisenkraft; Christian E Elger; Meir Bialer; Wolfram S Kunz
Journal:  Int J Mol Sci       Date:  2017-09-06       Impact factor: 5.923

Review 6.  Insights into Structural Modifications of Valproic Acid and Their Pharmacological Profile.

Authors:  Manish Kumar Mishra; Samiksha Kukal; Priyanka Rani Paul; Shivangi Bora; Anju Singh; Shrikant Kukreti; Luciano Saso; Karthikeyan Muthusamy; Yasha Hasija; Ritushree Kukreti
Journal:  Molecules       Date:  2021-12-24       Impact factor: 4.411

Review 7.  Use of Prescribed Psychotropics during Pregnancy: A Systematic Review of Pregnancy, Neonatal, and Childhood Outcomes.

Authors:  Catherine E Creeley; Lisa K Denton
Journal:  Brain Sci       Date:  2019-09-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.